Chevy, No snark intended, but you need to read up much more on the CF stuff. qdelfan correctly pointed out that Kalydeco was approved by England ahead of schedule and you told him to read the press release that it wouldn't work for 508. Kalydeco is labeled for 551 (not df508) and as recently as 2 weeks ago Vertex said that it wasn't rushing to negotiate a price on Kalydeco and that it expected reimbursements in England and EU and Canada to be coming throughout 2013. So this is much earlier than expected and likely at a good price for Vertex because it indicated it was holding out to protect the value of its drug. It also bodes well for further increased revenues when the Kalydeco label is expanded as Vertex already has a negotiated price for Kalydeco. Right now waiting on FDA to approve the study design for 809/770 which could be announced any day now.
I read that but thought they were expanding studies to see if it works on the df508 mutation which they said it didn't. my bad. not sure where I read it but they are trying for a larger population other than what is approved. Must be some other gene number I have confused. thx